We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » New Zealand Authorities Unveil Updated Recall Code

New Zealand Authorities Unveil Updated Recall Code

FDA Logo device green
September 4, 2015

Placing an emphasis on communication between stakeholders, New Zealand’s medical regulatory body has finalized an update to the code for executing medical device recalls.

“Although the document is much more comprehensive than the previous code, the principles of product recall remain the same and those regularly interacting with Medsafe (such as sponsors) and those receiving communications in the distribution chain will recognize that the processes described have been in place for some time, but have not been formally described in a code,” the agency says.

Among other things, the document defines common recall terminology, describes the levels of recall actions, details the responsibilities of sponsors, wholesalers, retailers and healthcare professionals, and gives an overview of Medsafe’s duties.

Medsafe published the draft version last December and sought comments through Feb. 27. The regulator notes that most submissions backed the code, with 18 stakeholders giving it their full support.

Eleven said they’d support it with a few adjustments, including changing certain terminology in the document and detailing the responsibilities of retailers who are not healthcare professionals.

Ten submitters did not support the code, citing the following reasons:

  • A lack of provisions for compensating pharmacists or general practitioners for their time and effort in aiding a recall;
  • The use of terminology for medical devices that could be considered inconsistent with EU or international usage; and
  • Inconsistency and rigidity of the recall process.

Among the changes from the draft to final version is the addition of healthcare professional to the levels of recall. The original version included wholesale, hospital/laboratory, retail and consumer levels.

The code will go into effect Dec. 1. Read the document at www.fdanews.com/090815-medsafe.pdf. — Elizabeth Hollis

Regulatory Affairs

Upcoming Events

  • 10Mar

    FDA Drug GMP Facility Inspections During the Pandemic

  • 16Mar

    Pharmaceutical Naming Regulation: Understanding the Latest Developments

  • 18Mar

    Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 30Mar

    Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges

  • 06Apr

    Medical Device Cybersecurity: Understand the Latest Developments

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • WhiteHouse.gif

    President Biden Issues Executive Order on U.S. Supply Chain

  • roche.gif

    Priority Healthcare Settles Diabetes Test Lawsuit with Roche for $43 Million

  • Effective text

    Pfizer/BioNTech Vaccine Equally Effective for All Age Groups, Israeli Study Says

  • Siemens Healthineers logo

    Siemens Healthineers’ COVID-19 Antigen Lab Test Receives CE Mark

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing